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Background: Hypertension is considered as a main risk factor for chronic kidney disease development and progression. Thus,
the control and evaluation of this disease with new software and devices are especially important in patients who suffer from
chronic kidney disease.
Objective: This study aimed to validate the QardioArm mobile device, which is used for blood pressure (BP) self-measurement
in patients who suffer from chronic kidney disease, by following the European Society of Hypertension International Protocol 2
(ESH-IP2) guidelines.
Methods: A validation study was carried out by following the ESH-IP2 guidelines. A sample of 33 patients with chronic kidney
disease self-measured their BP by using the QardioArm and Omron M3 Intellisense devices. Heart rate (HR), diastolic BP, and
systolic BP were measured.
Results: The QardioArm fulfilled the ESH-IP2 validation criteria in patients who suffered from chronic kidney disease.
Conclusions: Thus, this study is considered as the first validation using a wireless upper arm oscillometric device connected
to an app to measure BP and HR meeting the ESH-IP2 requirements in patients who suffer from chronic kidney disease. New
validation studies following the ESH-IP2 guidelines should be carried out using different BP devices in patients with specific
diseases.
(J Med Internet Res 2019;21(12):e14686)  doi: 10.2196/14686
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Increased afferent sympathetic activation may be an early event
in patients who suffer from chronic kidney disease [1]. Various
types of kidney damage may lead to a heightened sympathetic
drive by central integrative pathways to the hypothalamus [2,3].
The ensuing efferent response may lead to an increase in renin
activity, retention of sodium retention, and, eventually,
vasoconstriction, which may contribute to hypertension
development and propagation [4]. Hypertension may be
considered as a main risk factor for chronic kidney disease
development and progression. Thus, the control and evaluation
of this disease with new software and devices are especially
important in patients who suffer from chronic kidney disease.
Patients who suffer from chronic kidney disease must strictly
control their hypertension. Nevertheless, most of these patients
failed to control their blood pressure (BP), showing a lower
control rate compared with the general population [4-6].
Active involvement is required in patients with hypertension to
get a successful management of this disease. Encouragement
of home BP monitoring is considered as one of the main
measures that increased patient compliance with their treatment,
showing a great potential to improve hypertension control rates
[7-9]. To get efficient home BP monitoring, an accurate BP
measurement technique needs to be used by a validated device
[7]. Standard validation protocols are considered as objective
guidelines, which allow health care professionals to recommend
a device to their patients [10-13].
The Association for the Advancement of Medical
Instrumentation published a protocol to validate electronic and
aneroid sphygmomanometers in 1987. In 1990, the protocol of
the British Hypertension Society appeared as a new guideline.
Afterward, both protocols were revised in 1993 [10,11]. On the
basis of these experiences, the Working Group on Blood
Pressure Monitoring of the European Society of Hypertension
published a simplified international protocol to facilitate this
assessment process in 2002 to revise, unify, and simplify the
previous protocols [12]. In 2010, this last European Society of
Hypertension protocol was revised (ie, European Society of
Hypertension International Protocol 2 [ESH-IP2]), being more
exigent than the previous protocol [13]. These protocols have
been validated for the general adult population; nevertheless,
their validation needs to be carried out in special populations,
such as patients with chronic kidney disease [14].
Objectives
The hypothesis of this study was that QardioArm (Atten
Electronics Co) would be valid for self-measurement of BP and
heart rate (HR) in renal patients according to the ESH-IP2
guidelines. Hence, the purpose of this study was to validate the
QardioArm for BP self-measurement in patients who suffer
from chronic kidney disease, following the ESH-IP2 guidelines.
Methods
Study Design
This study was a descriptive investigation study to validate the
QardioArm device for the measurement of BP and HR in
patients with chronic kidney disease according to the ESH-IP2
guidelines [13]. It was performed between January 2019 and
May 2019.
Ethical Information
The Institutional Research and Ethical Committee at the
University of Extremadura (Badajoz, Spain), with the code
151/2019, approved this study. This study adhered to the
Declaration of Helsinki [15]. Participants were fully informed
about the study protocol. All participants signed their written
informed consent to participate in this study.
Devices
Omron M3 Intellisense
The Omron M3 Intellisense (Omron Healthcare) was considered
as the gold standard in this study. This device was validated in
the general population [16] and in patients with chronic kidney
disease [14] following the ESH-IP2 guidelines. This device has
been validated in comparison with a mercury
sphygmomanometer with a mean of −1.3 mm Hg (SD 4.3) for
systolic pressure and a mean of 2.1 mm Hg (SD 4.1) for diastolic
pressure in patients with chronic kidney disease [14]. In addition,
at the beginning of this study, the Omron M3 was evaluated in
comparison with a certified pressure device (the Omron M2)
[16] in 3 BP measurements to ensure the correct functioning of
the gold standard. The used Omron M3 Intellisense monitor
was purchased in a local market. The Omron M3 Intellisense
is an automated and oscillometric upper arm device for home
BP monitoring. This device comprised a standard arm cuff,
circumference ranging from 22 to 32 cm, and a large cuff,
circumference ranging from 32 to 42 cm. This device used
IntelliSense technology to acquire a comfortable controlled
inflation without pressure presetting or reinflation.
QardioArm
The QardioArm was selected as the test device in this study.
QardioArm is a fully automatic, noninvasive, wireless BP
monitor. QardioArm comprises a BP measurement system
intended to assess the diastolic BP and systolic BP and HR in
the adult population [17].
This device used an inflatable cuff that was wrapped around
the upper arm. Cuff circumference ranged from 22 to 37 cm.
A specific free Qardio app was downloaded from the Apple
App Store or Google Play Store. A device with Bluetooth 4.0,
iOS 7.0 (or later), and Android 4.4 KitKat (or later) was
required, being compatible with iPod, iPhone, Apple Watch,
iPad, and Android phones and tablets.
Furthermore, the QardioArm provided an automatic screen,
including graphics, to facilitate visual data interpretation. This
app is configured by issue reminders and warnings, and the
measurements and progress are real time shared with other users.
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All patients were recruited from the Fresenius Medical Care
dialysis clinics in Plasencia (Extremadura) and signed the
written informed consent.
Following the ESH-IP2 guidelines [13], 33 patients who fulfilled
the selection criteria were included in this study. Inclusion
criteria were women and men, aged at least 25 years, who
underwent hemodialysis treatment. Of the total participants,
this study included at least 10 men and 10 women, according
to the requirements of the guidelines. Exclusion criteria were
patients with a sustained arrhythmia or circulatory problems,
which are considered as contraindicated conditions for the use
of the cuff, as well as pregnant women.
Study Protocol
A total of 2 nurses with experience in BP measurement carried
out all assessments. The measurement room provided an
adequate temperature without any factor that could have
influenced the measurements, such as noise and distractions
[12,13].
Each participant self-reported birth date, sex, height, weight,
and body mass index (using the Quetelet index in kg/m2), and
the arm circumference was measured to ensure the adequate
cuff size.
Furthermore, participants were placed in sitting position in the
measurement room, and BP measurements were assessed after
a rest period (from 10 to 15 min). BP coinciding with the HR
was measured on the right arm in 30 patients with chronic
kidney disease, whereas BP was assessed on the left arm in 3
patients because of the presence of an arteriovenous fistula on
the right arm (n=2) and right hemiplegia (n=1). A total of 9
consecutive measurements were carried out following the
ESH-IP2 guidelines [12,13], alternating the 2 described devices
(the Omron M3 Intellisense and the QardioArm). All
measurements were recorded according to the following
protocol:
• BP A—entry BP using the standard device
• BP B—device detection BP using the test instrument
• BP 1—using standard device
• BP 2—using the test instrument
• BP 3—using standard device
• BP 4—using the test instrument
• BP 5—using the standard device
• BP 6—using the test instrument
• BP 7—using the standard device
At the same time of measurement, the patients remained quiet,
calm, sitting and without moving, placing the back straight,
maintaining the feet over the floor in parallel position, without
crossing their legs, and resting the arm over a flat surface, with
the hand palm upward and the elbow in a slightly flexed position
to place their fist at the height of the heart. The interval time
between BP measurements varied from 30 to 60 seconds [13].
All measurements were performed in the same room.
Data Analysis
Statistical analysis was performed by using IBM SPSS Statistics,
version 19 (SPSS Inc). Results were described in mean (SD).
The device accuracy following the ESH-IP2 guidelines was
based on a comparison between the measurements of the
reference (Omron M3) and test device (QardioArm).
For each patient, the device measurements such as BP 2, BP 4,
and BP 6 were first compared with the measurements such as
BP 1, BP 3, and BP 5, respectively, and also with the
measurements such as BP 3, BP 5, and BP 7, respectively.
Comparisons that were more favorable to the device were used.
Indeed, differences were classified separately for both diastolic
BP and systolic BP, depending on whether their values were
within 5, 10, or 15 mm Hg [13], and for HR, depending on
whether their values were within 3, 5, or 8 beats per minute.
Results were analyzed and detailed according to the ESH-IP2
requirements to conclude if the used device passed or failed to
pass the explained validation protocol. Parts 1 and 2 of the
validation protocol concern the differences in number of the
requested ranges for each individual measurement (99
measurements) and each individual patient (33 patients),
respectively [13].
Furthermore, Bland and Altman graphs were used to illustrate
the relationship between systolic BP differences (systolic BP
and device-reference) and mean systolic BP (device and
reference), diastolic BP differences (diastolic BP and
device-reference) and mean diastolic BP (device and reference),
or HR differences (HR and device-reference) and average HR
(device and reference).
Results
Patients With Chronic Kidney Disease
A sample of 35 patients with chronic kidney disease were
recruited to assess 33 participants who met the ESH-IP2
inclusion criteria, and 2 of them were excluded because of
device failure (n=1) and arrhythmias (n=1).
The remaining sample (n=33) was screened. There were 15
females and 18 males. The characteristics of the patients, such
as age, height, weight, body mass index, and arm circumference,
are presented in Table 1.
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Table 1. Sociodemographic characteristics of the patients.








48.0-91.072.13 (11.69)45.0-90.070.11 (11.11)45.0-91.071.03 (11.24)Age (years)
46.80-101.071.15 (18.31)46.5-100.070.33 (13.66)46.5-101.070.70 (15.68)Weight (kg)
141.0-174.0157.13 (10.77)155.0-180.0166.61 (5.63)141.0-180.0162.30 (9.52)Height (cm)
18.96-43.7229.14 (8.48)18.07-33.4825.26 (4.27)18.07-43.7227.02 (6.70)Body mass index (kg/m2)
215.0-350.0273.0 (38.06)220.0-310.0262.50 (24.15)215.0-350.0267.27 (31.18)Arm circumference (mm)
Blood Pressure Outcome Measurements
Validation findings for the QardioArm BP device following the
2010 ESH-IP2 are presented in Table 2 (Part 1), Table 3 (Part
2) and Textbox 1 (Part 3).
The measurement numbers differing from the standard device
(Omron M3) of 5, 10, and 15 mm Hg or less were presented in
Tables 2 and 3 and Textbox 1, for diastolic BP and systolic BP,
following the ESH-IP2 [13].
Mean differences between the test device and standard device
were 2.43 mm Hg (SD 4.15) for diastolic BP and 4.03 mm Hg
(SD 4.42) for systolic BP.
From these analyses, of 99 measurements, 81 differences for
systolic BP and 85 differences for diastolic BP showed an
absolute difference within 5 mm Hg (compared with at least 65
differences for diastolic BP and 73 differences for systolic BP
according to the ESH-IP2 criteria). Furthermore, 92 comparisons
for systolic BP and 95 comparisons for diastolic BP showed an
absolute difference within 10 mm Hg (compared with at least
81 differences for diastolic BP and 87 differences for systolic
BP according to the ESH-IP2 criteria).
In addition, of 99 differences, 96 for systolic BP and 95 for
diastolic BP exhibited an absolute difference within 15 mm Hg
(compared with at least 93 for diastolic BP and 96 for systolic
BP according to the ESH-IP2 criteria). Indeed, the validation
of part 1 of the device was successfully completed.
According to part 2 of the 2010 ESH-IP2 criteria, of 33 patients,
29 patients showed a minimum of 2 of 3 comparisons within a
5 mm Hg difference for systolic BP, and 30 patients showed a
minimum of 2 of 3 comparisons within a 5 mm Hg difference
for diastolic BP (compared with at least 24 patients for systolic
BP and diastolic BP according to the ESH-IP2 criteria).
Nevertheless, 2 patients showed their 3 differences outside 5
mm Hg for systolic BP, and no patients showed their 3
differences outside 5 mm Hg for diastolic BP (compared with
a maximum of 3 patients for diastolic BP and systolic BP
according to the ESH-IP2 criteria). Owing to these 2 described
conditions, validation of part 2 of the device was successfully
completed.
Therefore, part 3 of the QardioArm device validation was
completed, as both parts 1 and 2 were validated for diastolic
BP and systolic BP.
Table 2. Validation results of the Part 1 of the QardioArm blood pressure device according to the European Society of Hypertension International
Protocol 2010.





4.03 (4.42)Pass969281Systolic blood pressure
2.43 (4.15)Pass959585Diastolic blood pressure
aAccuracy is determined by the number differences in these ranges for both individual measurements (part 1) and individual subjects (part 2). To pass,
a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the IP.
cNot applicable.
dAchieved: as recorded by the device.
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Table 3. Validation results of the Part 2 of the QardioArm blood pressure device according to the European Society of Hypertension International
Protocol 2010.





aAccuracy is determined by the number differences in these ranges for both individual measurements (part 1) and individual subjects (part 2). To pass,
a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the IP.
cNot applicable.
dAchieved: as recorded by the device.
Textbox 1. Validation results of the Part 3 of the QardioArm blood pressure device according to the European Society of Hypertension International
Protocol 2010.
Validation results of QardioArm—Part 3
• Result: Pass
Heart Rate Outcome Measurements
Validation findings for the QardioArm HR device following
the 2010 ESH-IP2 are presented in Table 5 (Part 1), Table 6
(Part 2) and Textbox 2 (Part 3).
Measurement numbers differing from the standard device Omron
M3 of 3, 5, and 8 beats per minute or less are detailed in Tables
5 and 6 and Textbox 2 for HR. Mean differences between the
test device and standard device were 1.93 beats per minute (SD
3.04).
From these analyses, of 99 differences, 85 showed an absolute
difference within 3 beats per minute, 94 differences showed an
absolute difference within 5 beats per minute, and 95 differences
showed an absolute difference within 8 beats per minute. Thus,
part 1 device validation was successfully completed for the HR.
According to the part 2 of the 2010 ESH-IP2, of 33 participants,
29 showed a minimum of 2 of 3 comparisons within 3 beats per
minute difference for HR. Nevertheless, 1 participant showed
3 differences outside 3 beats per minute. As these 2 detailed
conditions were validated, the part 2 device validation was
successfully completed.
Therefore, part 3 of the QardioArm device validation was
completed, as both parts 1 and 2 were validated for HR.
Indeed, the QardioArm device met the validation criteria of the
ESH-IP2 for the diastolic BP, systolic BP, and HR for patients
who suffered from chronic kidney disease.
The prior findings coincided with the Bland and Altman graphs
that visually showed the differences between QardioArm device
measurements and Omron M3 measurements for systolic BP
(Figure 1), diastolic BP (Figure 1) and HR (Figure 1).
Table 5. Validation results of the Part 1 for the QardioArm heart rate device according to the European Society of Hypertension International Protocol
2010.






aAccuracy is determined by the number differences in these ranges for both individual measurements (part 1) and individual subjects (part 2). To pass,
a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the IP.
cNot applicable.
dAchieved: as recorded by the device.
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Table 6. Validation results of the Part 2 for the QardioArm heart rate device according to the European Society of Hypertension International Protocol
2010.




aAccuracy is determined by the number differences in these ranges for both individual measurements (part 1) and individual subjects (part 2). To pass,
a device must achieve all the minimum pass requirements shown.
bPass requirements: as required by the IP.
cNot applicable.
dAchieved: as recorded by the device.
Textbox 2. Validation results of the Part 3 for the QardioArm heart rate device according to the European Society of Hypertension International Protocol
2010.
Validation results QardioArm—Part 3
• Result: Pass
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Figure 1. Plots of (A) systolic blood pressure, (B) diastolic blood pressure, and (c) heart rate differences between the QardioArm and Omron M3.
Difference: systolic blood pressure (A), diastolic blood pressure (B), or heart rate (C) differences between the QardioArm and Omron M3. Mean: mean
systolic (A), diastolic (B), or heart rate (C) average values of the QardioArm and Omron M3.
Discussion
Principal Findings
Globally, the use of home BP monitoring is increasing in several
countries, being a useful complement to clinic measurements
with significant acceptance by patients with hypertension with
several advantages [7,9,18,19]. Patients who suffer from chronic
kidney disease may use a validated sphygmomanometer at home
because it seems to be especially cost-effective [6,7,18,20-22].
The main disadvantage of automated home sphygmomanometers
is their inaccuracy, although their accuracy is progressively
improving [13]. This inaccuracy is more frequent in populations
with specific diseases, which may require additional validation
tests [7,23]. Indeed, the European Society of Hypertension
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Practice Guidelines 2010 for home BP monitoring recommended
specific validation tests for patients with end-stage chronic
kidney disease [9]. Arterial stiffness may influence the
correspondence between readings measured by using mercury
and oscillometric devices [8,24].
Nevertheless, there is a lack of research studies, which validate
devices in patients with chronic kidney disease [14,24-27].
Further validation studies are necessary for patients with chronic
kidney disease. Indeed, further studies should specifically
investigate the validation of QardioArm in patients with chronic
kidney disease with arterial stiffness as a future line of research.
This research is considered as the first study investigating the
validation of a wireless upper arm oscillometric device
connected to an app to measure HR and BP in chronic kidney
disease patients. This validation has been carried out following
the ESH-IP2 guidelines, although a validated noninvasive
oscillometric upper arm device was used as a reference instead
of a mercury sphygmomanometer.
QardioArm has been previously validated for the general
population in the first place by our team [28] and later by other
authors [29]. In addition, our team validated QardioArm in
obese patients [30].
According to the results of our prior works, the number of
differences included in each category according to the ESH-IP2
(5, 10, and 15 mm Hg) for systolic BP and diastolic BP was
similar in the 3 validations [28-30], as parts 1 and 2 of the
protocol were passed. QardioArm in the general population
achieved better results in both phases of the protocol for systolic
and diastolic BP, especially in part 1 (higher differences in the
3 categories) [28]. Within phase 1, the differences obtained in
the systolic BP of renal patients in this study were very similar
to those of the general population [28], whereas the differences
obtained in the diastolic BP were more similar to the obese
population [30]. Phase 2 of this study was almost identical to
the 3 previous validations [28-30], with minor differences (1
or 2 individuals).
Following the ESH-IP2 guidelines, the findings of this study
showed that the QardioArm device successfully passed the
validation requirements for patients with chronic kidney disease
[13]. Nevertheless, our findings may not be extrapolated to other
specific populations with specific diseases such as elderly or
diabetic patients as well as pregnant women, as these conditions
have not been addressed. In addition, it should be considered
that patients with advanced chronic kidney disease could present
a specific chronic kidney disease type and future studies should
be carried out to develop new app validations according to the
specific recommendations in each kind of chronic kidney disease
patients Nevertheless, arterial stiffness measurements of patients
with chronic kidney disease involved in this study could be
useful, although the standard validation protocols did not require
these measures. Finally, consecutive sampling bias should be
considered in this study, and a simple randomization sampling
process could be more adequate for future studies.
Conclusions
The findings of this study are relevant because it is considered
as the first validation to show that a device connected to an app
to measure BP and HR met the requirements of the 2010
ESH-IP2 in the patients who suffer from chronic kidney disease.
Besides, the ESH-IP2 guidelines should stress on validating the
BP devices in other specific populations by publishing explicit
criteria for such a validation in these populations.
Finally, it is highly recommended to determine the accuracy of
this device in other populations with specific diseases such as
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